A little more than a year ago we were experiencing this same MIBG therapy for advanced-stage neuroblastoma in New York. We hope we are more prepared this time.
Justin fully understands what the next few days will bring: the lead-lined room, the isolation, the feelings of being a “caged animal” where whatever goes in, can’t come out. We’ve talked with him about how restricted Grandma and I will be from being able to take care of him, touch him, hug him and love on him.
Dr. John M. Maris, SU2C – St. Baldrick’s Pediatric Dream Team Leader
Even before he started medical school, physician and scientist John M. Maris, MD, was interested in neuroblastoma, a cancer that starts in young nerve cells and can spread quickly through a child’s body. It is one of the most common cancers in children, and the most common cancer in infants.
As he continued studying the disease, Dr. Maris became convinced that neuroblastoma was a genetic disease and that genetic research could unlock new treatments for kids with cancer. Since then, Dr. Maris has devoted his career to curing neuroblastoma, a passion that has fueled over two decades of research.
From a long list of innovative “big ideas,” the scientific reviewers representing both funding organizations had chosen the top four to submit detailed proposals. The experts agreed that any of these would be great investments, but for a grant of $14.5 million over four years, only one could be chosen.
The suspense ended with an enthusiastic round of applause when the winning Dream Team was announced at a reception tonight at the annual meeting of the American Association of Cancer Research (AACR). The evening’s emcee was actor Kyle MacLachlan, and speakers included Nobel Laureate Dr. Philip Sharp, St. Baldrick’s CEO Kathleen Ruddy, and 10-year-old cancer survivor Emma W. and her parents.
And the award goes to: